Close
  Indian J Med Microbiol
 

Figure 4: Kaplan–Meier log rank analysis of PTL patients divided by Ann Arbor stage and usage of rituximab. (a) OS and (b) PFS of PTL patients are shown. In patients without usage of rituximab, Ann Arbor stage was still a significant predictor of survival (OS: P =0.001; PFS: P =0.014). However, in patients with rituximab, Ann Arbor stage was not significantly associated with OS or PFS (P = 0.159 and P = 0.143, respectively). Also, rituximab failed to significantly improve survival in our cohort. PTL: primary testicular lymphoma; OS: overall survival; PFS: progression-free survival.

Figure 4: Kaplan–Meier log rank analysis of PTL patients divided by Ann Arbor stage and usage of rituximab. (<b>a</b>) OS and (<b>b</b>) PFS of PTL patients are shown. In patients without usage of rituximab, Ann Arbor stage was still a significant predictor of survival (OS: <i>P</i> =0.001; PFS: <i>P</i> =0.014). However, in patients with rituximab, Ann Arbor stage was not significantly associated with OS or PFS (<i>P</i> = 0.159 and <i>P</i> = 0.143, respectively). Also, rituximab failed to significantly improve survival in our cohort. PTL: primary testicular lymphoma; OS: overall survival; PFS: progression-free survival.